Internal medicine (Tokyo, Japan) · 2023
Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uehara Sanae, Naganuma Atsushi, Furuichi Nozomi, Furusawa Ai, Kaburagi Takuya, Naruse Hiroaki, Tomaru Shota, Sano Nozomi, Suzuki Yuhei, Masuda Tomoyuki, Hoshino Takashi, Yasuoka Hidetoshi, Tanaka Yuko, Saito Shuichi, Hatanaka Takeshi, Kakizaki Satoru
Аннотация
A woman in her 70s presented with gallbladder carcinoma with liver metastases and peritoneal dissemination. After standard chemotherapy failed, a liver biopsy was performed. A FoundationOne CDx analysis showed that the tumor mutational burden (TMB) was high (34 mutations/megabase). Treatment with pembrolizumab, which is an immune checkpoint inhibitor (ICI), resulted in a partial response, and there were no significant immune-related adverse events. According to recently published reports, the frequency of TMB-high biliary tract cancer (BTC) is 3.4-4%, which makes it extremely rare. In conclusion, ICIs may be effective in patients with TMB-high BTC.